Teena Chopra, MD
Infectious Disease · Detroit, MINPI 1447435540
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $229,611 of the $328,482 with a category attached, or 69.9%. 17 manufacturers reported payments, led by Pfizer at 41.8% of the total. Among infectious disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $1098.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$137K
- Shionogi Inc$47K
- Ferring Pharmaceuticals Inc.$46K
- Paratek Pharmaceuticals, Inc.$22K
- AbbVie$19K
- Cepheid$15K
- plus $43K from 11 others
Across 2 payments — averaging $40,277 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$81K
What the payments were for
- Consulting fees$83,19925%
- Speaking & faculty fees$229,61170%
- Travel & lodging$11,5294%
- Food & beverage$2,9731%
- Education$1,1700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer(2 entities) | 61 | $137,279 |
| Shionogi Inc | 46 | $46,585 |
| Ferring Pharmaceuticals Inc. | 35 | $45,751 |
| Paratek Pharmaceuticals, Inc. | 24 | $21,603 |
| AbbVie(2 entities) | 52 | $18,963 |
| Cepheid | 27 | $15,355 |
| Tetraphase Pharmaceuticals, Inc. | 11 | $12,167 |
| Invivyd Inc | 6 | $10,800 |
| Melinta Therapeutics, LLC | 23 | $4,208 |
| Merck | 2 | $3,763 |
| La Jolla Pharmaceutical Company | 1 | $2,466 |
| Roche Diagnostics Corporation | 1 | $2,400 |
| Modernatx, Inc. | 1 | $2,250 |
| GSK | 1 | $1,950 |
| Gilead | 6 | $1,890 |
| Seqirus USA Inc | 1 | $1,036 |
| Philips North America LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PAXLOVID$74,978
- Fetroja$40,687
- NUZYRA$21,114
- XPERT$17,024
- AVYCAZ$15,300
- Xerava$14,559
- PREVNAR 20$13,300
- PREVNAR - 13$12,995
- REBYOTA$11,344
- PEMGARDA$10,800
- GENEXPERT$9,000
- Rezzayo$2,763
- cobas Influenza A/B Nucleic acid test for use on the cobas Liat System$2,400
- Moderna Covid-19 Vaccine$2,250
- COMIRNATY$2,200
- TRUMENBA$2,100
- Veklury$1,890
- DALVANCE$1,235
- Vabomere$1,125
- TEFLARO$720
How this compares
$328,482 in reported general payments places this provider in the 95th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Detroit
- Indira BrarDetroit$323K
- Rodger MacarthurDetroit$150K
- Pranatharthi ChandrasekarDetroit$71K
- Mayur RameshDetroit$30K
- Marcus ZervosDetroit$26K
- Jack SobelDetroit$18K
- Smitha GudipatiDetroit$16K
- Ronaldo SupenaDetroit$14K
- Wasif HafeezDetroit$5K
- Nicholas YaredDetroit$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.